Hereditary transthyretin amyloidosis with polyneuropathy (damage to your peripheral nerves), (hATTR-PN), is a rare disease ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with ...

Wainzua had been previously approved for use by patients with ATTRv-PN in the United States, under the brand name Wainua.

Alnylam's Yvonne Greenstreet, at #STATSummit, predicts vutrisiran will become multibillion-dollar product for ...

Matt Mills is a former Trump supporter and avid voter. The 41-year-old from Brown County in southern Ohio has lupus, ...

A rabbit sensitized with myelin lipid galactocerebroside develops autoimmune demyelinating polyneuropathy. The nerve conduction study was performed prior to sensitization (a) and at the peak of ...

Ionis has five FDA-approved drugs and promising upcoming approvals. See more about IONS stock and why it warrants a Buy ...

The DogsBestLife dog breed guide provides comprehensive information on more than 100 dog breeds from the most popular to some ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty ...

Alnylam Pharmaceuticals has strong growth potential, particularly with Amvuttra for ATTR-CM. Read why ALNY stock justifies a ...

(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat ...